Table 2.

Antiretroviral Regimens

	Ledipasvir/Sofosbuvir for 8 Weeks (N = 27)
Receiving HIV treatment at screen, n (%)	27 (100)
Protease inhibitor, n (%)	7 (26)
Darunavir/ritonavir	3 (11)
Atazanavir/ritonavir	4 (15)
Non-nucleoside reverse transcriptase inhibitor, n (%)	9 (30)
Efavirenz	3 (11)
Rilpivirine	5 (18)
Nevirapine	1 (4)
Integrase inhibitor, n (%)	14 (52)
Raltegravir	3 (11)
Dolutegravir	6 (22)
Elvitegravir	5 (18)
Nucleoside reverse transcriptase inhibitor, n (%)	27 (100)
Tenofovir/emtricitabinea	23 (85)
Abacavir/lamivudine	4 (15)

Abbreviation: HIV, human immunodeficiency virus.

^aThere was 1 participant on tenofovir alafenamide and were 22 participants on tenofovir disoproxil fumarate.